Igovomab
Igovomab
Igovomab (pronounced as /iːˈɡɒvəmæb/) is a type of monoclonal antibody used in the detection and treatment of certain types of cancer. It is specifically designed to target and bind to the CA 125 antigen, which is commonly overexpressed in ovarian cancer cells.
Etymology
The term "Igovomab" is derived from the International Nonproprietary Names (INN), where "I-" stands for immunoglobulin, "govo-" represents the target, which is the CA 125 antigen associated with ovarian cancer, and "-mab" is a common suffix for monoclonal antibodies.
Usage
Igovomab is used in the detection and treatment of ovarian cancer. It is administered intravenously and works by binding to the CA 125 antigen on the surface of cancer cells, allowing the immune system to more effectively target and destroy these cells.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- CA 125: A protein that is a biomarker for ovarian cancer.
- Ovarian cancer: A type of cancer that begins in the ovaries.
- Immunoglobulin: A type of protein produced by plasma cells and lymphocytes and characteristic of these types of cells.
See Also
External links
- Medical encyclopedia article on Igovomab
- Wikipedia's article - Igovomab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski